Skip to content
value.today

Alimera Sciences Inc.

Total raised
$174 M
5 rounds on record
Latest round
$81 M
Mar 2023
First round on record
Aug 2009
Today
Acquired
See the company page

Alimera Sciences Inc. is listed today as Alimera Sciences: market value, financials and filings are on its company page.

Acquired

Matched to this startup by its exact name; the buyer's report is the source.

Acquisition of Alimera Sciences Inc.
AcquiredBuyerAcquisition dateCompletionPriceStakeSource
Alimera Sciences, IncANI Pharmaceuticals, Inc.2024—$419 M—Annual report

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Alimera Sciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2023$81 MNo. 5$50 to $250 million

Alimera Sciences Inc.: Raise no. 5, Mar 2023

Investors in this round

16 investors had bought by the notice of May 31, 2023: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 41 investors are named for Alimera Sciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$81 M of $81 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David S. Holland · Executive Officer
  • Philip S. Ashman · Executive Officer
  • Richard S. Eiswirth, Jr. · Executive Officer, Director
  • Russell S. Skibsted · Executive Officer
  • Adam S. Morgan · Director
  • Daniel S. Myers · Director
  • Erin S. Parsons · Director
  • Garheng S. Kong · Director
  • John J. Snisarenko · Director
  • Michael S. Kaseta · Director
  • Peter J. Pizzo III · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The amounts set forth in Item 13(a) and 13(b) represent a two tranche closing. The first tranche, consisting of $12,000,000 of securities closed on 03/24/2023 and the second tranche, consisting of $69,000,000 of securities closed on 05/17/2023.”

Signed by Richard S. Eiswirth, Jr., Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed May 31, 2023. Read the notice at the SEC.

equity, optionsSEC
Apr 2021$10 MNo. 4$10 to $50 million

Alimera Sciences Inc.: Raise no. 4, Apr 2021

Investors in this round

1 investor had bought by the notice of Apr 27, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 41 investors are named for Alimera Sciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Philip Holland · Executive Officer · Chief Marketing Officer, Senior Vice President Corporate Communication and Managed Markets
  • J. Philip Jones · Executive Officer · Chief Financial Officer
  • Philip Philip Ashman · Executive Officer · Chief Operating Officer and Senior Vice President Commercial Operations Europe
  • Richard S. Eiswirth · Executive Officer, Director · President, Chief Executive Officer and Director
  • Brian K. Halak · Director
  • C. Daniel Myers · Director
  • Garheng K. Kong · Director
  • James R. Largent · Director
  • John J. Snisarenko · Director
  • Mary T. Szela · Director
  • Peter J. Pizzo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard S. Eiswirth, President, Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Apr 27, 2021. Read the notice at the SEC.

equitySEC
Jan 2014$38 MNo. 3$10 to $50 million

Alimera Sciences Inc.: Raise no. 3, Jan 2014

Investors in this round

21 investors had bought by the notice of Feb 18, 2014: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 41 investors are named for Alimera Sciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$38 M of $38 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,250,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • C. Daniel Myers · Executive Officer, Director
  • Richard S. Eiswirth · Executive Officer
  • Brian S. Halak · Director
  • Calvin J. Roberts · Director
  • Garheng S. Kong · Director
  • Glen S. Bradley · Director
  • James R. Largent · Director
  • Mark S. Brooks · Director
  • Peter J. Pizzo · Director
  • Phil J. Tracy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen and Company, LLC (CRD 7616) · broker-dealer Cowen and Company, LLC (CRD 7616) · New York, New YorkSold in CA, CT, IL, MA, NC, NJ, NY

Signed by C. Daniel Myers, President and CEO. Source: SEC Form D, newest notice filed Feb 18, 2014. Read the notice at the SEC.

equitySEC
Oct 2012$40 MNo. 2$10 to $50 million

Alimera Sciences Inc.: Raise no. 2, Oct 2012

Investors in this round

0 investors had bought by the notice of Oct 5, 2012: 0 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 41 investors are named for Alimera Sciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • C. Daniel Myers · Executive Officer, Director
  • Richard S. Eiswirth · Executive Officer
  • Brian S. Halak · Director
  • Calvin W. Roberts · Director
  • Glen S. Bradley · Director
  • James R. Largent · Director
  • Mark S. Brooks · Director
  • Peter J. Pizzo · Director
  • Phil W. Tracy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by C. Daniel Myers, President and CEO. Source: SEC Form D, newest notice filed Oct 5, 2012. Read the notice at the SEC.

equity, optionsSEC
Aug 2009$5 MNo. 1$2 to $10 million

Alimera Sciences Inc.: Raise no. 1, Aug 2009

Investors in this round

25 investors had bought by the notice of Sep 4, 2009: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 41 investors are named for Alimera Sciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Daniel Myers · Executive Officer, Director
  • David Holland · Executive Officer
  • Kenneth Green · Executive Officer
  • Richard Eiswirth · Executive Officer
  • Susan Caballa · Executive Officer
  • Anders Hove · Director
  • Brian Halak · Director
  • Bryce Youngren · Director
  • Calvin Roberts · Director
  • Mark Brooks · Director
  • Philip Tracy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard Eiswirth, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 4, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Alimera Sciences Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (May 2023).

    SEC Form D (revenue range) · May 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2023

Products and services#

No products or services of Alimera Sciences Inc. are on record.

Investors#

41 named in official filings. Open an investor to see everything it has backed.

Investors in Alimera Sciences Inc.
InvestorKindAmountRoundRoleSource
Bavp, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Caligan Partners LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Calvin W. RobertsPersonnot statednot statedHeld Series B and C preferred stock, director (Form 3, 2010)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Mgmt III, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Private Design Fund III, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Private Design Fund II, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Private Design International II, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Domain Partners VI, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
DP VI Associates, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Intersouth Affiliates V LPFund or asset managernot statednot statedHeld Series A, B and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Intersouth Associates VII, LLCOthernot statednot statedHeld Series C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Intersouth Associates VI, LLCOthernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Intersouth Associates V, LLCOthernot statednot statedHeld Series A, B and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Intersouth Partners VII L.P.Fund or asset managernot statednot statedHeld Series C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Intersouth Partners VI LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Intersouth Partners V, L.P.Fund or asset managernot statednot statedHeld Series A, B and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Palo Alto Healthcare Fund II L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Palo Alto Healthcare Fund, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Palo Alto Healthcare Master Fund, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Palo Alto InvestorsFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Palo Alto Investors LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Polaris Venture Management Co IV LLCVenture capitalnot statednot statedHeld Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Polaris Venture Partners Entrepreneurs Fund IV LPVenture capitalnot statednot statedHeld Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Polaris Venture Partners IV LPVenture capitalnot statednot statedHeld Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Scale Venture Management I, LLCVenture capitalnot statednot statedHeld Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Sofinnova Management VIII, L.L.C.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Sofinnova Venture Partners VIII, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
VEF Management IV, LLCFund or asset managernot statednot statedHeld Series B, C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Velan Capital Holdings LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Velan Capital Investment Management LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Velan Capital Management LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Velan Capital Master Fund LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Velan Capital SPV I LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Venrock Associates IV L.P.Fund or asset managernot statednot statedHeld Series B, C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Venrock Entrepreneurs Fund IV L.P.Fund or asset managernot statednot statedHeld Series B, C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Venrock Management IV, LLCFund or asset managernot statednot statedHeld Series B, C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Venrock Partners, L.P.Fund or asset managernot statednot statedHeld Series B, C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Venrock Partners Management, LLCFund or asset managernot statednot statedHeld Series B, C and C-1 preferred stock, 10% owner (Form 3, 2010)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 25 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Alimera Sciences Inc.
NameRoleNamed in
David S. HollandExecutive officerMay 2023
Philip S. AshmanExecutive officerMay 2023
Richard S. Eiswirth, Jr.Executive officerMay 2023
Russell S. SkibstedExecutive officerMay 2023
David Philip HollandChief Marketing Officer, Senior Vice President Corporate Communication and Managed MarketsApr 2021
J. Philip JonesChief Financial OfficerApr 2021
Philip Philip AshmanChief Operating Officer and Senior Vice President Commercial Operations EuropeApr 2021
Richard S. EiswirthPresident, Chief Executive Officer and DirectorApr 2021
C. Daniel MyersExecutive officerFeb 2014
Charles Daniel MyersExecutive officerSep 2009
David HollandExecutive officerSep 2009
Kenneth GreenExecutive officerSep 2009
Richard EiswirthExecutive officerSep 2009
Susan CaballaExecutive officerSep 2009
Adam S. MorganDirectorMay 2023
Daniel S. MyersDirectorMay 2023
Erin S. ParsonsDirectorMay 2023
Garheng S. KongDirectorMay 2023
John J. SnisarenkoDirectorMay 2023
Michael S. KasetaDirectorMay 2023
Peter J. Pizzo IIIDirectorMay 2023
Richard S. Eiswirth, Jr.DirectorMay 2023
Daniel R. MyersDirectorApr 2023
Erin R. ParsonsDirectorApr 2023
James R. LargentDirectorApr 2023
Roger J. SawhenyDirectorApr 2023
Brian K. HalakDirectorApr 2021
C. Daniel MyersDirectorApr 2021
Garheng K. KongDirectorApr 2021
Mary T. SzelaDirectorApr 2021
Peter J. PizzoDirectorApr 2021
Richard S. EiswirthPresident, Chief Executive Officer and DirectorApr 2021
Brian S. HalakDirectorFeb 2014
Calvin J. RobertsDirectorFeb 2014
Glen S. BradleyDirectorFeb 2014
Mark S. BrooksDirectorFeb 2014
Phil J. TracyDirectorFeb 2014
Calvin W. RobertsDirectorOct 2012
Phil W. TracyDirectorOct 2012
Anders HoveDirectorSep 2009

About

American biopharmaceutical sales company.

Acquired (Jan 1, 2024). Acquired by ANI Pharmaceuticals, Inc..